Aligos Therapeutics, Inc. ALGS 深 滬
已收盤 08-08 16:00:00 美东时间
7.69
-0.440
-5.41%
華盛通- 最 高8.49
- 今 開8.20
- 成交量 8.50万股
- 最 低 7.54
- 昨 收 8.13
- 總市值 4702.28万
- 52周最高 46.80
- 市盈率 靜 --
- 換手率 1.39%
- 52周最低 3.76
- 委 比 -34.53%
- 總股本 611.48万
- 歷史最高 937.75
- 量 比 1.42
- 振 幅 11.69%
- 歷史最低 3.76
- 每 手 1
- 風險率 10.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
In the last three months, 6 analysts have published ratings on Mirum Pharmaceut...
08-09 02:02
Aligos Therapeutics Q2 EPS $(1.53) Beats $(2.36) Estimate, Sales $965.00K Beat $433.33K Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.36) by 35.25 percent. This is a 304 percent decrease over earnings of $0.75 per share from
08-07 04:14
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Aligos Therapeutics reported second-quarter 2025 progress, highlighting the initiation of the Phase 2 B-SUPREME study for ALG-000184, a potential best-in-class treatment for chronic hepatitis B. The company presented promising 96-week Phase 1 data, showing sustained viral suppression and safety. ALG-055009 demonstrated efficacy in reducing liver fat and atherogenic lipids in metabolic dysfunction-associated steatohepatitis. ALG-097558 clinical tr...
08-06 20:05
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
Aligos Therapeutics (NASDAQ: ALGS), a clinical-stage biotech company focused on treating liver and viral diseases, announces it will report its Q2 2025 financial results on August 6 after U.S. markets close. The company specializes in developing best-in-class therapies for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, and coronaviruses. Forward-looking statements are included, subject to risks inherent in drug development...
07-30 20:05
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
Aligos Therapeutics has appointed Kieron Wesson, PhD, as Vice President and Head of Chemistry, Manufacturing, and Controls (CMC). Wesson brings over 20 years of experience in pharmaceutical development and will oversee all CMC-related matters, including the upcoming Phase 2 study of ALG-000184. Previously, he held leadership roles at Kezar Life Sciences, AN2 Therapeutics, and Anacor Pharmaceuticals. Aligos, a clinical-stage biotech company specia...
06-18 12:00
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Aligos Therapeutics授予26,000股股票期权给新员工，作为入职激励。期权基于公司2024年激励计划，授予日为2025年6月10日，行权价为当日收盘价。股票分四年 vesting，25%在第一年，剩余部分按月分摊。公司致力于开发肝脏和病毒疾病的最佳疗法。</p>
06-13 12:00
“北京普惠健康保”特药清单扩容，涵盖肿瘤等121种国内及海外药品
转自：北京日报客户端 为进一步提升药品保障待遇，减轻参保人用药负担，2025年度“北京普惠健康保”特药清单重磅升级，特药清单由106种升级至121种。新版特药...
06-10 10:33
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
Aligos Therapeutics的管理层将于6月5日在Jefferies Global Healthcare Conference上发表演讲，投资者可通过公司官网观看直播及回放。公司专注于开发肝病和病毒性疾病的最佳疗法，涵盖慢性乙肝、MASH及冠状病毒等领域。
05-29 12:00
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
Throughout the last three months, 4 analysts have evaluated Mirum Pharmaceutica...
05-10 04:01
